相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。MAP17 Is a Necessary Activator of Renal Na+/Glucose Cotransporter SGLT2
Michael J. Coady et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
Hiddo J. L. Heerspink et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
Sunder Mudaliar et al.
DIABETES CARE (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Uric acid in metabolic syndrome: From an innocent bystander to a central player
Mehmet Kanbay et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2016)
Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus
Panai Song et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2016)
Renal epithelium regulates erythropoiesis via HIF-dependent suppression of erythropoietin
Navid M. Farsijani et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Mitochondrial Pathology and Glycolytic Shift during Proximal Tubule Atrophy after Ischemic AKI
Rongpei Lan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
Yoon-Kyung Chang et al.
PLOS ONE (2016)
Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron
Anita T. Layton et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2016)
The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
Volker Vallon
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Silvio E. Inzucchi et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
Caroline Bonner et al.
NATURE MEDICINE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Localizations of Na+-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart
Ivana Vrhovac et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2015)
Acute SGLT inhibition normalizes O-2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats
Julie O'Neill et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus
Yuliya Lytvyn et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
Yukihiro Chino et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2014)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2014)
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
J. Bolinder et al.
DIABETES OBESITY & METABOLISM (2014)
β-hydroxybutyrate: Much more than a metabolite
John C. Newman et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
SGLT2 inhibitors in the treatment of type 2 diabetes
Farhad M. Hasan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria
Suzanne Geerlings et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
Masanori Yokono et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport
M. A. Abdul-Ghani et al.
JOURNAL OF INTERNAL MEDICINE (2014)
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
William L. Baker et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2014)
Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors
Raymond V. Oliva et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2014)
Functional Role of Glucose Metabolism, Osmotic Stress, and Sodium-Glucose Cotransporter Isoform-Mediated Transport on Na+/H+ Exchanger Isoform 3 Activity in the Renal Proximal Tubule
Thaissa Dantas Pessoa et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
Naoto Terami et al.
PLOS ONE (2014)
Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice
Muralikrishna Gangadharan Komala et al.
PLOS ONE (2014)
Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models
M. Suzuki et al.
NUTRITION & DIABETES (2014)
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
Anthony H. Barnett et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves β-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat
Henrik H. Hansen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension
Florian Gembardt et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
Volker Vallon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice
T. Nagata et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
T. Heise et al.
DIABETES OBESITY & METABOLISM (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
J-F Yale et al.
DIABETES OBESITY & METABOLISM (2013)
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
William N. Washburn et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)
Jan N. Basile
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Sodium-Glucose Co-Transporter 2 Inhibitors and the Potential for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Mellitus
Robert M. Guthrie
POSTGRADUATE MEDICINE (2013)
Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus
Volker Vallon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2013)
Effects of a New SGLT2 Inhibitor, Luseogliflozin, on Diabetic Nephropathy in T2DN Rats
Naoki Kojima et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences
Ivan Sabolic et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2012)
Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
Scott C. Thomson et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2012)
Renal Function in Diabetic Disease Models: The Tubular System in the Pathophysiology of the Diabetic Kidney
Volker Vallon et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 74 (2012)
Na+-D-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose-Absorption and Glucose-Dependent Incretin Secretion
Valentin Gorboulev et al.
DIABETES (2012)
Effects of SGLT2 inhibitors on cardiovascular outcomes
Celine Foote et al.
DIABETES & VASCULAR DISEASE RESEARCH (2012)
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Jan Bolinder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2
Charles S. Hummel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2011)
The proximal tubule in the pathophysiology of the diabetic kidney
Volker Vallon
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2011)
Early Growth Retardation and Insulin Resistance in JAZF1 KO Mice
Hui-Young Lee et al.
DIABETES (2011)
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
S. Sha et al.
DIABETES OBESITY & METABOLISM (2011)
SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
Volker Vallon et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
Frank A. Holtkamp et al.
KIDNEY INTERNATIONAL (2011)
Biology of Human Sodium Glucose Transporters
Ernest M. Wright et al.
PHYSIOLOGICAL REVIEWS (2011)
SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
Michael J. Jurczak et al.
DIABETES (2011)
Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target
Rene Santer et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats
F. R. Macdonald et al.
DIABETES OBESITY & METABOLISM (2010)
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
J. E. Gerich
DIABETIC MEDICINE (2010)
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis
G. M. Magee et al.
DIABETOLOGIA (2009)
Repression via the GATA box is essential for tissue-specific erythropoietin gene expression
Naoshi Obara et al.
BLOOD (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phlorizin: a review
JRL Ehrenkranz et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Diabetic nephropathy: Diagnosis, prevention, and treatment
JL Gross et al.
DIABETES CARE (2005)
Expression of hypoxia-inducible factor-1α and -2α in hypoxic and ischemic rat kidneys
C Rosenberger et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2002)
分享论文
